Metabolic Syndrome Augments the Risk of Early Neurological Deterioration in Acute Ischemic Stroke Patients Independent of Inflammatory Mediators: A Hospital-Based Prospective Study
Table 1
Comparison of clinical characteristics between patients with and without END.
Characteristics
With END ()
Without END ()
value
Age, year
68.7 ± 9.8
65.6 ± 8.9
0.040
Male (%)
32 (65.3)
108 (67.9)
0.733
Prehistory
Smoking (%)
14 (28.6)
52 (32.7)
0.587
Drinking habits (%)
15 (30.6)
43 (27.0)
0.626
Hypertension (%)
31 (63.3)
120 (75.5)
0.101
Diabetes (%)
23 (46.9)
41 (25.8)
0.005
Hyperlipidemia (%)
10 (20.4)
28 (17.6)
0.658
Atrial fibrillation (%)
6 (12.2)
12 (7.5)
0.307
Coronary heart disease (%)
6 (12.2)
16 (10.1)
0.664
Previous antiplatelet (%)
4 (8.2)
17 (10.7)
0.607
Previous stain (%)
3 (6.1)
15 (9.4)
0.471
SBP, mmHg
150.2 ± 17.1
148.7 ± 17.8
0.603
DBP, mmHg
85.0 ± 10.6
85.1 ± 11.6
0.971
BMI, kg/m2
25.5 ± 1.6
25.8 ± 1.7
0.242
NIHSS, score
3 (2, 5)
3 (2, 4)
0.193
Time from onset to admission, h
24 (12, 24)
24 (8, 24)
0.970
Length of stay, day
18 (15.5, 21.5)
13 (11, 14)
0.001
MetS (%)
29 (59.2)
58 (36.5)
0.005
Number of metabolic factors
0.026
0-1
5 (10.2)
40 (25.2)
2
15 (30.6)
61 (38.4)
3
22 (44.8)
46 (28.9)
4-5
7 (14.3)
12 (7.5)
Stroke subtype (TOAST)
0.864
LAA
28 (57.1)
90 (56.6)
CE
5 (10.2)
11 (6.9)
SVO
14 (28.6)
52 (32.7)
Others
2 (4.1)
6 (3.8)
Laboratory data
Leukocyte count, 109/L
7.5 ± 1.5
6.9 ± 1.8
0.038
Platelet count, 109/L
186 (156, 228)
190 (145, 210)
0.817
Fibrinogen, mg/dL
307.8 ± 98.7
286.6 ± 66.8
0.088
hsCRP, mg/L
6.0 (2.0, 11.5)
2.0 (0.9, 5.0)
0.001
Homocysteine, umol/L
14.4 (12.0, 21.7)
11.1 (13.0, 18.0)
0.049
Fasting plasma glucose, mmol/L
8.0 (5.9, 9.9)
5.4 (5.0, 6.1)
0.001
TC, mmol/L
4.8 ± 1.3
4.5 ± 1.0
0.194
TG, mmol/L
1.3 (1.0, 2.2)
1.3 (1.0, 1.7)
0.307
HDL, mmol/L
1.4 (1.1, 1.6)
1.3 (1.1, 1.5)
0.192
LDL, mmol/L
2.3 (1.7, 2.9)
2.3 (1.9, 2.9)
0.750
MetS, metabolic syndrome; END, early neurological deterioration; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism.
